18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
18:22 , May 25, 2018 |  BC Week In Review  |  Clinical News

Sesen reports Phase III data for bladder cancer candidate Vicinium

Sesen Bio Inc. (NASDAQ:SESN) (formerly Eleven Biotherapeutics Inc.) said Vicinium (VB4-845) led to a complete response rate of 42% at three months in 77 evaluable bladder cancer patients with carcinoma in situ (CIS) in the...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
20:11 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends continuation of Phase III Vicinium trial in NMIBC

Eleven Biotherapeutics Inc. (NASDAQ:EBIO) said an independent DSMB recommended continuation of its Phase III trial evaluating Vicinium (VB4-845) via intravesical instillation to treat high-grade non-muscle invasive bladder cancer (NMIBC) patients who previously failed treatment with...
22:54 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

RNA BiTEs

BioNTech AG believes its RNA therapeutics platform can produce bispecific antibodies that circumvent the manufacturing and short plasma half-life problems of other technologies, and thinks its approach can accelerate the development timeline for bispecific T...
23:02 , Jun 27, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms; drug delivery

TECHNOLOGY: Nucleic acids; other A method for delivering bispecific T cell-engaging antibodies as engineered mRNAs could prolong the serum half-life of the antibodies to treat cancer. mRNA encoding bispecific antibodies targeting CD3 and a second tumor...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
16:41 , Jun 22, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Diagnostic assays; cell-free assays; plasma markers A five-protein signature in extracellular vesicles isolated from plasma could help diagnose PDAC. The assay involves two steps: addition of patient plasma samples to a gold plasmonic chip-based microarray...
23:24 , Apr 24, 2017 |  BC Extra  |  Clinical News

Team creates lung organoid with branching structures

In a paper published Monday in Nature Cell Biology, researchers at Columbia University developed three-dimensional lung bud organoids (LBOs) from human pluripotent stem cells and said they could be used to model lung disease. Researchers generated...
20:03 , Dec 13, 2016 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A magnetic field cytometry-based method of detecting CTCs could help diagnose breast, prostate and other cancers. The method involved tagging tumor cell surface markers such as epithelial cell adhesion molecule (EpCAM) in patient...